Bambusa and Aspen join biotech IPO queue

13 October 2026

US biotech companies Bambusa Therapeutics and Aspen Neuroscience have filed for initial public offerings (IPOs), seeking funding as they prepare further trials of bispecific antibodies and a patient-derived cell therapy for Parkinson’s disease, respectively.

Both submitted registration statements to the Securities and Exchange Commission (SEC) on October 9. Their proposed offerings add to a queue that includes US drug developers City Therapeutics, Iambic Therapeutics and Lycia Therapeutics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Biotechnology